Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

Core Viewpoint - ANIXA BIOSCIENCES INC is identified as a promising momentum stock with a Momentum Style Score of A and a Zacks Rank of 2 (Buy), indicating potential for near-term price increases [3][12]. Momentum Style Score Analysis - The Momentum Style Score incorporates price changes and earnings estimate revisions, which are critical for assessing stock performance [2][9]. - ANIX's shares have increased by 7.39% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 5.43% during the same period [6]. - Over the past month, ANIX's price change is 27.82%, significantly higher than the industry's 6.65% [6]. Long-Term Performance Metrics - In the last quarter, ANIX shares rose by 12.21%, and over the past year, they increased by 27.34%, while the S&P 500 only moved 4.46% and 13.71%, respectively [7]. - The average 20-day trading volume for ANIX is 154,337 shares, indicating a bullish trend when combined with rising stock prices [8]. Earnings Outlook - In the past two months, one earnings estimate for ANIX has been revised upward, while none have been lowered, leading to an increase in the consensus estimate from -$0.41 to -$0.38 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions, suggesting positive sentiment around future earnings [10].

Core Insights - Anixa Biosciences, Inc. is gaining media attention for its breast cancer vaccine, which has the potential to transform breast cancer treatment and prevention [1][2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, targeting various cancers including lung, colon, and prostate [5] Vaccine Mechanism - The breast cancer vaccine is designed to train the immune system to recognize and eliminate cancerous cells by targeting the lactation protein α-lactalbumin, which is expressed in malignant breast cancer cells [2] - This vaccine aims to activate cytotoxic T cells to provide preemptive immune protection against emerging breast tumors [2] Media Coverage - The New York Post and Fox News have featured Anixa's breast cancer vaccine, highlighting its potential impact on breast cancer treatment [1][3]

SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congr ...

Core Viewpoint - Anixa Biosciences Inc (ANIX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - Anixa Biosciences is projected to earn -$0.38 per share for the fiscal year ending October 2025, reflecting a year-over-year change of 2.6% [7]. - Over the past three months, the Zacks Consensus Estimate for Anixa has increased by 7.3%, indicating a positive revision trend [7]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6][8]. - Anixa's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9].

Company Overview - ANIXA BIOSCIENCES INC is part of the Medical group, which consists of 999 companies and is currently ranked 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 503 companies and is ranked 78 in the Zacks Industry Rank [5] Performance Metrics - Year-to-date, ANIXA BIOSCIENCES INC has increased by approximately 20.3%, outperforming the average loss of 4.4% in the Medical group [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has risen by 7.3% over the past quarter, indicating improved analyst sentiment and earnings outlook [3] Comparative Analysis - Another outperforming stock in the Medical sector is Cellectar Biosciences, Inc., which has returned 54.4% year-to-date [4] - Cellectar Biosciences, Inc. belongs to the Medical - Products industry, which has a lower ranking (134) and has increased by 5.2% this year [6]

Core Insights - Anixa Biosciences, Inc. is advancing a breast cancer vaccine that aims to train the immune system to identify and eliminate cancerous cells before they develop into invasive tumors [2][3] - The vaccine specifically targets α-lactalbumin, a protein expressed in the breast during lactation, which is also found in malignant breast cancer cells [2] - The company has completed enrollment in the Phase 1 clinical trial for the vaccine and is optimistic about its potential impact on breast cancer treatment and prevention [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by targeting the natural ligand of the FSHR receptor on tumor cells [4] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers such as lung, colon, and prostate [4]

Revenue - No revenue was generated during the three-month and six-month periods ended April 30, 2025 and 2024[84][92] Expenses - Research and development expenses decreased by approximately $324,000 to approximately $1,322,000 in the three months ended April 30, 2025, compared to approximately $1,646,000 in the same period of 2024[87] - General and administrative expenses decreased by approximately $140,000 to approximately $1,681,000 in the three months ended April 30, 2025, from approximately $1,821,000 in the same period of 2024[88] - Research and development expenses for cancer vaccines and CAR-T therapeutics were approximately $1,873,000 and $1,001,000, respectively, during the six months ended April 30, 2025[94] - General and administrative expenses decreased by approximately $566,000 to approximately $3,515,000 in the six months ended April 30, 2025, from approximately $4,081,000 in the same period of 2024[96] Income - Interest income decreased by approximately $96,000 to approximately $190,000 in the three months ended April 30, 2025, from approximately $287,000 in the same period of 2024[89] - Interest income decreased by approximately $243,000 to approximately $363,000 in the six months ended April 30, 2025, from approximately $606,000 in the same period of 2024[97] Assets and Cash Flow - Total current assets decreased by approximately $4,596,000 to approximately $16,766,000 at April 30, 2025, compared to approximately $21,362,000 at October 31, 2024[100] - Cash used in operating activities was approximately $4,407,000 during the six months ended April 30, 2025[101] Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $24,000 to approximately $52,000 in the six months ended April 30, 2025, from approximately $76,000 in the same period of 2024[98] Internal Controls - There was no change in internal control over financial reporting during the three months ended April 30, 2025, that materially affected internal control[117] - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures are effective as of the end of the reporting period[116] Compensation Allocation - The company allocates certain internal compensation costs to research and development expenses based on management's estimates of employee time and effort[113]

Financial Data and Key Metrics Changes - The company has a strong balance sheet with $17 million in cash, providing a runway of approximately 2.5 years, which is considered ample in the current industry context [6][9][13] - Historical cash burn averages between $5 million and $7 million per year, indicating a capital-efficient business model [8][15] Business Line Data and Key Metrics Changes - The company is advancing two lead clinical programs: a breast cancer vaccine and an ovarian cancer CAR T therapy, both currently in Phase 1 clinical trials with promising clinical data [3][16] - The breast cancer vaccine is funded by a U.S. Government grant, which helps keep cash burn low [17][34] Market Data and Key Metrics Changes - The breast cancer market is large and well-known, while the ovarian cancer market, though smaller, presents a significant unmet medical need with poor outcomes [5] - The company is targeting both neoadjuvant and primary prevention markets for its breast cancer vaccine, indicating a broad market strategy [40] Company Strategy and Development Direction - The company leverages partnerships with top-tier academic institutions like Moffitt Cancer Center and Cleveland Clinic to enhance its research capabilities without incurring high costs [4][10] - The strategy focuses on advancing clinical programs through early stages and partnering with pharmaceutical companies for later-stage development and commercialization [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data being generated, particularly regarding the safety and efficacy of the ovarian cancer CAR T therapy, with encouraging survival rates observed in treated patients [27][28] - The company aims to present final data from the Phase 1 trial of the breast cancer vaccine at the San Antonio Breast Cancer Symposium in December, indicating a proactive approach to sharing results [39] Other Important Information - The company has maintained consistent insider buying over the years, reflecting management's confidence in the business [7] - There are no outstanding warrants, preferred stock, or debt, which positions the company favorably for future financing [13] Q&A Session Summary Question: What is the current status of the ovarian cancer CAR T therapy? - The therapy is in Phase 1 trials, with encouraging safety profiles and overall survival rates observed in treated patients [27][28] Question: How is the breast cancer vaccine funded? - The breast cancer vaccine is fully funded by a U.S. Government grant, which helps minimize cash burn [17][34] Question: What are the next steps for the breast cancer vaccine program? - The company plans to present final data from the Phase 1 trial at the San Antonio Breast Cancer Symposium in December and is preparing for a Phase 2 trial [39][40]

Core Insights - Anixa Biosciences has made significant progress in its clinical and pre-clinical development programs in 2025, maintaining fiscal discipline while advancing its oncology treatment initiatives [1][5] Financial Performance - The company has maintained an average annual cash burn of approximately $5–6 million, which is significantly lower than typical for development-stage biotechnology companies [2] - In the most recent fiscal year, the cash burn was limited to $7 million while advancing two clinical trials [2] - Anixa ended the most recent quarter with over $17 million in cash and no debt, providing more than two years of operational runway [3] Capital Structure - Anixa has a clean capital structure with approximately 32 million common shares outstanding and no warrants [4] - Directors and senior management have consistently purchased stock on the open market, collectively investing millions of dollars, indicating strong belief in the company's long-term value [4] Clinical Programs - The CAR-T therapy program targeting recurrent, platinum-resistant ovarian cancer is progressing, with three dose-escalation cohorts completed in the Phase 1 trial [6][7] - Encouraging signs of efficacy have been observed, with one patient surviving two years post-treatment, significantly exceeding the typical four-month median survival for this population [7] - The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is nearing enrollment completion in its Phase 1 trial, with over 70% of patients showing protocol-defined immune responses [9][11] Future Milestones - Key milestones for the second half of 2025 include final Phase 1 data for the breast cancer vaccine, anticipated FDA interactions, and the initiation of the fourth cohort for the CAR-T ovarian cancer program [15][17] - The company is preparing to extend its vaccine platform to target prostate, lung, and colon cancers, addressing substantial unmet needs in these areas [13][14]